Despite a challenging fiscal year, Carl Zeiss Meditec AG (CZMWF) leverages new product launches and strategic market ...

Carl Zeiss Meditec has strong fundamentals and growth potential. It has impressive free cash flow and rising shareholder ...

There's been a notable change in appetite for Carl Zeiss Meditec AG shares in the week since its yearly report, with the stock down 15% to €49.30. Revenues were €2.1b, approxi ...

EQS-News: Carl Zeiss Meditec AG / Key word (s): Annual Report/Annual Results Carl Zeiss Meditec closes fiscal year 2023/24 with slight decline in revenue- Adjusted EBIT forecast achieved 11.12.2024 ...

ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology ...

The broader Asia-Pacific region was also a weak spot, with organic growth in ophthalmology devices down 4.5% for the year, ...

RBC Capital analyst Jack Reynolds-Clark maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report) today and set a price target of €70.00. The company’s shares closed yesterday at €58.93.

At Carl Zeiss, the battle against these diseases has a tradition dating back to Robert Koch’s groundbreaking discovery. To this day, the company continues to set the standard with commitment and ...

German optics giant Carl Zeiss AG has signaled a major commitment ... The center represents a deeper integration of the Indian team into the company's global operations. Manufacturing expansion ...

Carl Zeiss Meditec's stock continues to face significant market challenges, with shares trading at €55.70 on XETRA, marking a 1.2% decline. This downturn represents a dramatic shift from the company's ...

ZEISS Research Microscopy Solutions and AI pathology leader Mindpeak have joined forces to develop an integrated Multiplex ...